Physician profile
Michael Sananman
NPI 1407826514
$1,215.92
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $242.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $264.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $237.39 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $142.63 | 2019-2020 | |
| Amgen INC. | $76.99 | 2019 | |
| Ucb, INC. | $67.31 | 2019-2020 | |
| Lilly USA, LLC | $66.17 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $55.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.19 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $48.37 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $41.57 | 2019 | |
| Allergan, INC. | $32.19 | 2020 | |
| Emd Serono, INC. | $28.45 | 2019 | |
| Ge Healthcare | $26.16 | 2019 | |
| Neurocrine Biosciences, INC. | $23.25 | 2020 | |
| Acorda Therapeutics, INC | $14.48 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $14.40 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $12.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sananman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.